Roth Says Buy the Dip in Synta Pharma as Co. Reached Ideal Patient Population in Latest Trial
June 04, 2013 at 15:58 PM EDT
On the heels of a 34 percent plunge in shares of Synta Pharmaceuticals (NASDAQ: SNTA ) on Monday amid shorter survival benefits from GALAXY-1 Phase 2b/3 trial of ganetespib, Roth Capital's Joseph Pantginis is recommending investors buy the dip in the stock. Pantginis believes Synta found the ideal patient
